SCHEMBL4053030

SCHEMBL4053030

c1ccc(-c2cnc3nc(-c4ccc5c(c4)OCCO5)[nH]c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.45
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 2/20 0.44
HDAC6 Q9UBN7 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PARP1 P09874 2/20 0.44
TNKS O95271 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
CYP3A4 P08684 1/20 0.42
TGFBR1 P36897 1/20 0.41
CSNK1A1 P48729 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059829 0.93 PARP1 (0.52) AURKAKDM4EMEN1ALDH1A1MAPT
SCHEMBL4053288 0.82 AURKA (0.56) AURKAMEN1ALDH1A1MAPTHPGD
SCHEMBL4059131 0.81 AURKA (0.56) AURKACYP3A4CSNK1G2GUSBRAB9A
SCHEMBL13608549 0.81 TNKS (0.49) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL4058315 0.79 AURKA (0.52) AURKACYP3A4CSNK1G2GUSBUSP30
SCHEMBL4062970 0.79 TGFBR1 (0.54) AURKAKDM4EMEN1ALDH1A1HPGD
SCHEMBL4055850 0.78 SCD (0.53) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL4051595 0.78 AURKA (0.57) AURKAKDM4EMEN1ALDH1A1MAPT
SCHEMBL4058862 0.78 CLK1 (0.46) AURKAKDM4EMEN1ALDH1A1MAPT
SCHEMBL4055474 0.78 PTGS2 (0.50) AURKAKDM4EMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885KDM4E 496/4885MEN1 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.